How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/pulmonary-mycobacterium-avium-complex-infection.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-11 · How we verify

Pulmonary Mycobacterium avium complex infection — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pulmonary Mycobacterium avium complex infection (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pulmonary Mycobacterium avium complex infection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zithromax	azithromycin	Pfizer Inc.	Macrolide antibiotic (azalide)	Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor	1991-11-01
Biaxin	clarithromycin	Generic (originally Abbott/AbbVie)	Macrolide Antimicrobial [EPC]	Potassium voltage-gated channel subfamily H member 2	1991-10-31
Trecator	ETHIONAMIDE	Pfizer	Antimycobacterial		1965-01-01
Mycobutin	Mycobutin	Harriet Shezi Children's Clinic		Bacterial DNA-directed RNA polymerase, DNA-directed RNA polymerase subunit beta

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Generic (originally Abbott/AbbVie) · 1 drug in Pulmonary Mycobacterium avium complex infection
Harriet Shezi Children's Clinic · 1 drug in Pulmonary Mycobacterium avium complex infection
Pfizer · 1 drug in Pulmonary Mycobacterium avium complex infection
Pfizer Inc. · 1 drug in Pulmonary Mycobacterium avium complex infection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pulmonary Mycobacterium avium complex infection:

Cite this brief

Drug Landscape (2026). Pulmonary Mycobacterium avium complex infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pulmonary-mycobacterium-avium-complex-infection. Accessed 2026-06-11.

Pulmonary Mycobacterium avium complex infection full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing